Are you Dr. Portlock?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 83 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000
Summary
- Dr. Carol Portlock, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York. She is affiliated with Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1975 - 1976- Stanford Health Care-Sponsored Stanford UniversityResidency, Radiology-Diagnostic, 1974 - 1975
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1971 - 1974
Stanford University School of MedicineClass of 1971
Certifications & Licensure
NY State Medical License 1988 - 2019
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
Clinical Trials
- Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Start of enrollment: 1998 Jun 01
- Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma Start of enrollment: 1999 Dec 01
- Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma Start of enrollment: 2007 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 76 citationsPatterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.Anita Kumar, Fushen Sha, Ahmed Toure, Ahmet Dogan, Andy Ni
Blood Cancer Journal. 2019-05-20 - 14 citationsClinical presentation determines selection of patients for initial observation in mantle cell lymphoma.Anita Kumar, Zhitao Ying, Anna Alperovich, Ahmet Dogan, Paul A. Hamlin
Haematologica. 2019-04-01 - 54 citationsBrentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, Heiko Schöder, Paul M. Barr
Blood. 2016-09-15
Press Mentions
Pay It Forward: For the Lymphoma Research Foundation, Personal Connections Drive FundingSeptember 15th, 2020
